Pre-b cell colony enhancing factor/nampt/visfatin in inflammation and obesityrelated disorders

Current Pharmaceutical Design

Volumn 16, Issue 17, 2010, Pages 1913-1920

  Moschen, Alexander R ^a   Gerner, Romana R ^a   Tilg, Herbert ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Fatty liver disease; Inflammation; NAMPT; PBEF; Visfatin

Indexed keywords

INSULIN; INTERLEUKIN 6; N [4 (1 BENZOYL 4 PIPERIDINYL)BUTYL] 3 (3 PYRIDINYL)ACRYLAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; SIRTUIN; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA;

ARTHRITIS; ARTICLE; BIOSYNTHESIS; CELL CYCLE; CYTOKINE PRODUCTION; DRUG TARGETING; ENZYME ACTIVITY; FATTY LIVER; HORMONE ACTION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LONGEVITY; METABOLISM; MITOCHONDRIAL RESPIRATION; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; SEPSIS; STRESS; ANIMAL; BLOOD; COMPLICATION; PATHOPHYSIOLOGY;

ANIMALS; FATTY LIVER; HUMANS; INFLAMMATION; NAD; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953530684     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791208947     Document Type: Article

References (93)

1. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994; 14: 1431-7.
2. Luk T, Malam Z, Marshall JC. Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol 2008; 83: 804-16.
3. Sommer G, Garten A, Petzold S, Beck-Sickinger AG, Bluher M, Stumvoll M, et al. Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. Clin Sci (Lond) 2008; 115: 13-23.
4. Martin PR, Shea RJ, Mulks MH. Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence. J Bacteriol 2001; 183: 1168-74.
5. Muller WE, Perovic S, Wilkesman J, Kruse M, Muller IM, Batel R. Increased gene expression of a cytokine-related molecule and profilin after activation of Suberites domuncula cells with xenogeneic sponge molecule(s). DNA Cell Biol 1999; 18: 885-93.
6. Fujiki K, Shin DH, Nakao M, Yano T. Molecular cloning and expression analysis of the putative carp (Cyprinus carpio) pre-B cell enhancing factor. Fish Shellfish Immunol 2000; 10: 383-5.
7. Ognjanovic S, Bao S, Yamamoto SY, Garibay-Tupas J, Samal B, Bryant-Greenwood GD. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J Mol Endocrinol 2001; 26: 107-17.
8. Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004; 113: 1318-27.
9. Khanna-Gupta A, Berliner N. Vitamin B3 boosts neutrophil counts. Nat Med 2009; 15: 139-41.
10. Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O, et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphori-bosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 2002; 32: 3225-34.
11. Garten A, Petzold S, Korner A, Imai S, Kiess W. Nampt: linking AD biology, metabolism and cancer. Trends Endocrinol Metab 2009; 20: 130-8.
12. Preiss J, Handler P. Enzymatic synthesis of nicotinamide mononucleotide. J Biol Chem 1957; 225: 759-70.
13. Wang Y, Lam JB, Lam KS, Liu J, Lam MC, Hoo RL, et al. Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 2006; 66: 11462-70.
14. Kitani T, Okuno S, Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor. FEBS Lett 2003; 544: 74-8.
15. Fukuzawa M, Satoh J, Muto G, Muto Y, Nishimura S, Miyaguchi S, et al. Inhibitory effect of nicotinamide on in vitro and in vivo production of tumor necrosis factor-alpha. Immunol Lett 1997; 59: 7-11.
16. Ungerstedt JS, Blomback M, Soderstrom T. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin Exp Immunol 2003; 131: 48-52.
17. Szabo C. Nicotinamide: a jack of all trades (but master of none?). Intensive Care Med 2003; 29: 863-6.
18. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Retraction. Science 2007; 318: 565.
19. Revollo JR, Korner A, Mills KF, Satoh A, Wang T, Garten A, et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007; 6: 363-75.
20. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
21. Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005; 16: 421-7.
22. Marchesini G, Forlani G. NASH: from liver diseases to metabolic disorders and back to clinical hepatology. Hepatology 2002; 35: 497-9.
23. Bugianesi E, Marzocchi R, Villanova N, Marchesini G. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. Best Pract Res Clin Gastroenterol 2004; 18: 1105-16.
24. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000; 343: 1467-76.
25. Sanyal AJ. Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Practice Gastroenterol Hepatol 2005; 2: 46-53.
26. Mizuhara H, O'Neill E, Seki N, Ogawa T, Kusunoki C, Otsuka K, et al. T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med 1994; 179: 1529-37.
27. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-50.
28. McClain CJ, Song Z, Barve SS, Hill DB, Deaciuc I. Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2004; 287: G497-502.
29. Zekry A, McHutchison JG, Diehl AM. Insulin resistance and steatosis in hepatitis C virus infection. Gut 2005; 54: 903-6.
30. Akerman P, Cote P, Yang SQ, McClain C, Nelson S, Bagby GJ, et al. Antibodies to tumor necrosis factor-alpha inhibit liver regeneration after partial hepatectomy. Am J Physiol 1992; 263: G579-85.
31. Cressman DE, Greenbaum LE, DeAngelis RA, Ciliberto G, Furth EE, Poli V, et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996; 274: 1379-83.
32. Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001; 34: 1158-63.
33. Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Taioli E, et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 274-80.
34. Tanaka M, Nozaki M, Fukuhara A, Segawa K, Aoki N, Matsuda M, et al. Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway. Biochem Biophys Res Commun 2007; 359: 194-201.
35. Revollo JR, Grimm AA, Imai S. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol 2007; 23: 164-70.
36. Otero M, Lago R, Gomez R, Lago F, Dieguez C, Gomez-Reino JJ, et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1198-201.
37. Koczan D, Guthke R, Thiesen HJ, Ibrahim SM, Kundt G, Krentz H, et al. Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules. Eur J Dermatol 2005; 15: 251-7.
38. Korner A, Garten A, Bluher M, Tauscher R, Kratzsch J, Kiess W. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007; 92: 4783-91.
39. Ye SQ, Simon BA, Maloney JP, Zambelli-Weiner A, Gao L, Grant A, et al. Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am J Respir Crit Care Med 2005; 171: 361-70.
40. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, et al. Visfatin, an Adipocytokine With Pro-Inflammatory and Immunomodulating Properties. J Immunol 2007; 178: 1748-58.
41. de Boer JF, Bahr MJ, Boker KH, Manns MP, Tietge UJ. Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis. Am J Physiol Gastrointest Liver Physiol 2009; 296: G196-G201.
42. Zhong M, Tan HW, Gong HP, Wang SF, Zhang Y, Zhang W. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf) 2008; 69: 878-84.
43. Zhu J, Schott M, Liu R, Liu C, Shen B, Wang Q, et al. Intensive glycemic control lowers plasma visfatin levels in patients with type 2 diabetes. Horm Metab Res 2008; 40: 801-5.
44. Erdem G, Dogru T, Tasci I, Bozoglu E, Muhsiroglu O, Tapan S, et al. The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus. Diabetes Res Clin Pract 2008; 82: 214-8.
45. Retnakaran R, Youn BS, Liu Y, Hanley AJ, Lee NS, Park JW, et al. Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross-sectional study. Clin Endocrinol (Oxf) 2008; 69: 885-93.
46. Haus JM, Solomon TP, Marchetti CM, O'Leary VB, Brooks LM, Gonzalez F, et al. Decreased visfatin after exercise training correlates with improved glucose tolerance. Med Sci Sports Exerc 2009; 41: 1255-60.
47. Liu SW, Qiao SB, Yuan JS, Liu DQ. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf) 2009; 71: 202-7.
48. Nusken KD, Petrasch M, Rauh M, Stohr W, Nusken E, Schneider H, et al. Active visfatin is elevated in serum of maintenance haemodialysis patients and correlates inversely with circulating HDL cholesterol. Nephrol Dial Transplant 2009; 24: 2832-8.
49. Jongwutiwes T, Lertvikool S, Leelaphiwat S, Rattanasiri S, Jultanmas R, Weerakiet S. Serum visfatin in Asian women with polycystic ovary syndrome. Gynecol Endocrinol 2009; 25: 536-42.
50. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 2007; 56: 451-8.
51. Wang SN, Yeh YT, Wang ST, Chuang SC, Wang CL, Yu ML, et al. Visfatin-a proinflammatory adipokine-in gallstone disease. Am J Surg 2010; 199(4): 459-65.
52. Moschen AR, Molnar C, Wolf AM, Weiss H, Graziadei I, Kaser S, et al. Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. J Hepatol 2009; 51: 765-77.
53. Manco M, Fernandez-Real JM, Equitani F, Vendrell J, Valera Mora ME, Nanni G, et al. Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women. J Clin Endocrinol Metab 2007; 92: 483-90.
54. Aller R, de Luis DA, Izaola O, Sagrado MG, Conde R, Velasco MC, et al. Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease. Dig Dis Sci 2009; 54: 1772-7.
55. Garten A, Petzold S, Barnikol-Oettler A, Korner A, Thasler WE, Kratzsch J, et al. Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. Biochem Biophys Res Commun 2010; 391: 376-81.
56. Brentano F, Schorr O, Ospelt C, Stanczyk J, Gay RE, Gay S, et al. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum 2007; 56: 2829-39.
57. Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, Eyileten T, et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant 2008; 23: 959-65.
58. Li Y, Zhang Y, Dorweiler B, Cui D, Wang T, Woo CW, et al. Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. J Biol Chem 2008; 283: 34833-43.
59. Lee WJ, Wu CS, Lin H, Lee IT, Wu CM, Tseng JJ, et al. Visfatininduced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway. Int J Obes (Lond) 2009; 33: 465-72.
60. Tilg H, Moschen AR. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci (Lond) 2008; 114: 275-88.
61. Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54: 2911-6.
62. Gosset M, Berenbaum F, Salvat C, Sautet A, Pigenet A, Tahiri K, et al. Crucial role of visfatin/pre-B cell colony-enhancing factor in matrix degradation and prostaglandin E2 synthesis in chondrocytes: possible influence on osteoarthritis. Arthritis Rheum 2008; 58: 1399-409.
63. Tilg H, Moschen AR, Kaser A, Pines A, Dotan I. Gut, inflammation and osteoporosis: basic and clinical concepts. Gut 2008; 57: 684-94.
64. Moschen AR, Geiger S, Gerner R, Tilg H. Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease. Mutat Res 2009; [Epub ahead of print].
65. Moschen AR, Kaser A, Enrich B, Ludwiczek O, Gabriel M, Obrist P, et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 2005; 54: 479-87.
66. Romacho T, Azcutia V, Vazquez-Bella M, Matesanz N, Cercas E, Nevado J, et al. Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia 2009; 52: 2455-63.
67. Kim SR, Bae YH, Bae SK, Choi KS, Yoon KH, Koo TH, et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta 2008; 1783: 886-95.
68. Adya R, Tan BK, Chen J, Randeva HS. Pre-B cell colony enhancing factor (PBEF)/visfatin induces secretion of MCP-1 in human endothelial cells: role in visfatin-induced angiogenesis. Atherosclerosis 2009; 205: 113-9.
69. Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, Eyileten T, et al. Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT. A novel marker of endothelial damage? Clin Transplant 2009; 23: 241-8.
70. Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 2004; 279: 50754-63.
71. Yang H, Yang T, Baur JA, Perez E, Matsui T, Carmona JJ, et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell 2007; 130: 1095-107.
72. Ho C, van der Veen E, Akawi O, Pickering JG. SIRT1 markedly extends replicative lifespan if the NAD+ salvage pathway is enhanced. FEBS Lett 2009; 583: 3081-5.
73. van der Veer E, Ho C, O'Neil C, Barbosa N, Scott R, Cregan SP, et al. Extension of human cell lifespan by nicotinamide phosphori-bosyltransferase. J Biol Chem 2007; 282: 10841-5.
74. Hassa PO, Hottiger MO. The functional role of poly(ADP-ribose)polymerase 1 as novel coactivator of NF-kappaB in inflammatory disorders. Cell Mol Life Sci 2002; 59: 1534-53.
75. Oliver FJ, Menissier-de Murcia J, Nacci C, Decker P, Andriantsitohaina R, Muller S, et al. Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J 1999; 18: 4446-54.
76. Rajamohan SB, Pillai VB, Gupta M, Sundaresan NR, Birukov KG, Samant S, et al. SIRT1 promotes cell survival under stress by deacetylation-dependent deactivation of poly(ADP-ribose) polymerase 1. Mol Cell Biol 2009; 29: 4116-29.
77. Nakahata Y, Sahar S, Astarita G, Kaluzova M, Sassone-Corsi P. Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1. Science 2009; 324: 654-7.
78. Ramsey KM, Yoshino J, Brace CS, Abrassart D, Kobayashi Y, Marcheva B, et al. Circadian clock feedback cycle through NAMPT-mediated NAD+biosynthesis. Science 2009; 324: 651-54.
79. Busso N, Karababa M, Nobile M, Rolaz A, Van Gool F, Galli M, et al. Pharmacological inhibition of nicotinamide phosphoribosyl transferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS ONE 2008; 3: e2267.
80. Van Gool F, Galli M, Gueydan C, Kruys V, Prevot PP, Bedalov A, et al. Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner. Nat Med 2009; 15: 206-10.
81. Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28: 370-9.
82. Holen K, Saltz LB, Hollywood E, Burk K, Hanauske AR. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest New Drugs 2008; 26: 45-51.
83. von Heideman A, Berglund A, Larsson R, Nygren P. Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data. Cancer Chemother Pharmacol 2010; 65(6): 1165-72.
84. Drevs J, Loser R, Rattel B, Esser N. Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma. Anticancer Res 2003; 23: 4853-8.
85. Cea M, Zoppoli G, Bruzzone S, Fruscione F, Moran E, Garuti A, et al. APO866 activity in hematologic malignancies: a preclinical in vitro study. Blood 2009; 113: 6035-7.
86. Beauparlant P, Bedard D, Bernier C, Chan H, Gilbert K, Goulet D, et al. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777. Anticancer Drugs 2009; 20: 346-54.
87. Kato H, Ito E, Shi W, Alajez NM, Yue S, Lee C, et al. Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma. Clin Cancer Res 2010; 16: 898-911.
88. Galli M, Van Gool F, Rongvaux A, Andris F, Leo O. The nicotinamide phosphoribosyltransferase: a molecular link between metabolism, inflammation, and cancer. Cancer Res 2010; 70: 8-11.
89. Vaziri H, Dessain SK, Ng EE, Imai SI, Frye RA, Pandita TK, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001; 107: 149-59.
90. Luo J, Su F, Chen D, Shiloh A, Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000; 408: 377-81.
91. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W, et al. Mammalian SIRT1 represses forkhead transcription factors. Cell 2004; 116: 551-63.
92. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005; 434: 113-8.
93. Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltrans-ferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 2003; 63: 7436-42.